Editek Gains US OK For Verdict Products
Editek of the USA has received pre-marketing clearance from the US Food and Drug Administration for two of its Verdict products to test substance abuse, one-step Verdict THC (marijuana) and the Verdict barbiturates test.
These approvals follow pre-market clearances for its one-step Verdict cocaine and opiates tests, which all use the company's patented immunochromatographic technology. Editek has also filed an application with the FDA for its Verdict PCP test, whilst continuing development on its amphetamines test.
In addition, the company has seven EZ-Screen substance abuse tests on the market which include assays for cannabinoids, cocaine, opiates, amphetamines, PCP and barbiturates, as well as the recently-cleared EZ-Screen Profile test which is the size of a credit card and which can test for all the aforementioned drugs in under 10 minutes.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze